Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.

OP is considering using KX-826 for hair loss due to side effects from other treatments like Minoxidil and finasteride. Users discuss the risks and safety of KX-826, with some suggesting caution due to its status as a research chemical.

The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.

A 42-year-old experienced significant hair regrowth after 12 weeks on an oral combination of finasteride (1 mg) and minoxidil (2.5 mg), with noticeable improvements and no side effects. The user is considering continuing the treatment for a year due to the unexpected positive results.

Hair loss treatments RU and topical spironolactone were compared. No specific results or conclusions were provided.

The conversation is about adding dermarolling to a hair loss treatment routine. The user seeks recommendations for dermarollers, stamps, or pens, emphasizing the importance of quality and proper cleaning.

Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.

The conversation is about seeking hairline regrowth results using RU58841, dermarolling, and Nizoral. The user cannot tolerate finasteride and finds minoxidil ineffective.

The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.

The conversation discusses the potential of a new hair loss drug, CB-03-01, with users sharing their experiences and seeking advice on dosages and application methods. One user mentions using topical finasteride, minoxidil, dermarolling, and a clean diet for hair maintenance but is interested in CB-03-01 due to side effects from finasteride.

Users discuss alternatives to DHT blockers for hair loss, suggesting minoxidil, microneedling, natural DHT blockers, and scalp massages. Some explore RU58841, ketoconazole, hair transplants, and hair systems due to side effects from finasteride and dutasteride.

A Danish citizen warns against NordicHairGrowth.com, claiming it falsely advertises products for treating androgenic alopecia. The company's ingredients and claims are disputed, including a non-existent patented ingredient RP-24, and a non-verifiable clinical trial.

The conversation is about a person's hair loss treatment routine, which includes Metformin, sleep in darkness, avoiding EMF at night, Nizoral, Dermarolling, Castor oil, and Collagen. They have observed less hair shedding and increased hair volume.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The user seeks input from medical professionals and scientists on these treatments.

The conversation discusses using a dermapen for microneedling to treat hair loss, with specific mention of using Minoxidil, Finasteride, Dutasteride, RU58841, KX-826, and other topicals. The user experienced side effects like palpitations and itching after microneedling and applying these treatments.

Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.

A user is waiting for pyrilutamide delivery and is seeking reviews, especially regarding side effects. No reviews have been mentioned in the conversation.

Obscure hair loss topicals like Alfatradiol, Fluridil, and Stemoxydine are discussed. They may be considered for those not responding well to common treatments like Minoxidil and Finasteride.

Low-level laser therapy hats for hair loss, with skepticism about their effectiveness and cost. Users suggest trying affordable alternatives instead of expensive options.

Switching from Arimidex to Raloxifene worsened hair loss despite using Dutasteride. The user added oral Minoxidil, dermastamping, and RU58841 to their regimen to address the issue.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

A user's 3-month progress with a combination of finasteride, minoxidil and dermarolling for hair loss; other users shared their experiences and advice.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

The conversation discusses the use of TRT, dutasteride, minoxidil, and potentially RU58841 for hair loss. Concerns about the risk of developing Cutis verticis gyrata with minoxidil and TRT are raised.

A user is seeking a hair loss formula containing Redensyl and Capixyl without caffeine, Saw Palmetto, or other herbs. They want recommendations for such a product.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.